切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2020, Vol. 14 ›› Issue (03) : 222 -225. doi: 10.3877/cma.j.issn.1674-0793.2020.03.014

所属专题: 文献

论著

高危胃肠间质瘤的临床病理特征及预后分析
李亚平1,(), 朱明杰1, 蒋鸿元1   
  1. 1. 614000 四川省乐山市人民医院胃肠外科
  • 收稿日期:2019-07-09 出版日期:2020-06-01
  • 通信作者: 李亚平
  • 基金资助:
    四川省医学会科研项目(Q18066)

Pathological characteristics and prognosis of high risk gastrointestinal stromal tumors

Yaping Li1,(), Mingjie Zhu1, Hongyuan Jiang1   

  1. 1. Department of Gastrointestinal Surgery, Leshan People’s Hospital, Leshan 614000, China
  • Received:2019-07-09 Published:2020-06-01
  • Corresponding author: Yaping Li
  • About author:
    Corresponding author: Li Yaping, Email:
引用本文:

李亚平, 朱明杰, 蒋鸿元. 高危胃肠间质瘤的临床病理特征及预后分析[J/OL]. 中华普通外科学文献(电子版), 2020, 14(03): 222-225.

Yaping Li, Mingjie Zhu, Hongyuan Jiang. Pathological characteristics and prognosis of high risk gastrointestinal stromal tumors[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(03): 222-225.

目的

分析高危胃肠间质瘤(GIST)临床特征及预后影响因素。

方法

回顾性分析2009年8月至2016年2月乐山市人民医院收治的241例高危GIST患者临床资料,分析其临床特征及预后影响因素。

结果

男女比例为1.131,年龄构成以中老年为主,40岁以上人群构成比达90.87%(219/241)。原发部位以胃和小肠为主,胃50例(20.75%),小肠121例(50.21%)。首发症状以消化道症状为主,临床表现不典型。R0切除232例(96.27%),术后复发转移率为25.31%(61/241),1、3、5年无复发生存率分别为97.23%、86.56%和75.86%,无复发生存时间为(53.12±13.08)个月。肿瘤最大径(RR=4.780,95% CI:3.716~6.052)、核分裂像(RR=5.411,95% CI:2.195~7.119)是影响高危GIST 5年无复发生存率的独立危险因素,服用靶向药物是保护因素(RR=0.504,95% CI:0.288~0.883),差异有统计学意义(P<0.001)。

结论

高危GIST临床特征不明显,预后受核分裂像、肿瘤最大径和服用靶向药物影响。

Objective

To investigate the clinical characteristics and prognosis of high-risk gastrointestinal stromal tumors (GIST).

Methods

The clinical data of two hundred and forty-one high-risk GIST patients admitted to Leshan People’s Hospital from August 2009 to February 2016 were analyzed retrospectively.

Results

The proportion of men and women was 1.131. The age composition was mainly middle-aged and old people, and the proportion of people over 40 years old was 90.87% (219/241). The primary sites were stomach and small intestine, with 50 cases (20.75%) in stomach and 121 cases (50.21%) in small intestine. The first symptoms were mainly gastrointestinal symptoms, and the clinical manifestations were not typical. 232 patients (96.27%) underwent R0 resection and the recurrence and metastasis rate was 25.31% (61/241). The recurrence free survival rates of 1-, 3-, 5- year were 97.23%, 86.56% and 75.86%, respectively. The recurrence free survival time was (53.12±13.08) months. The tumor maximum diameter (RR=4.780, 95% CI: 3.716-6.052), mitotic image (RR=5.411, 95% CI: 2.195-7.119) were independent risk factors for 5-year recurrence free survival of high-risk GIST, while taking targeted drugs was the protective factor (RR=0.504, 95% CI: 0.288-0.883), the differences were statistically significant (P<0.001).

Conclusion

The clinical features of high-risk GIST are not obvious, and the prognosis is affected by mitotic image, the maximum diameter of the tumor and taking targeted drugs.

表1 241例高危胃肠道间质瘤预后的单因素分析
图1 241例高危胃肠道间质瘤患者无复发生存曲线
表2 影响高危胃肠间质瘤患者预后的多因素回归分析
[1]
Luo XF, Zhou LH. Prognostic significance of neutrophil to lymphocyte ratio in patients with gastrointestinal stromal tumors: A Meta-analysis[J]. Clin Chim Acta, 2018, 477(106): 7-12.
[2]
Keung EZ, Raut CP. Management of gastrointestinal stromal tumors[J]. Surg Clin North Am, 2017, 97(2): 437-452.
[3]
Liu W, Zeng X, Wu X, et al. Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: A single-institutional experience in China[J]. Medicine (Baltimore), 2017, 96(32): e7668.
[4]
Verde F, Hruban RH, Fishman EK. Small bowel gastrointestinal stromal tumors: multidetector computed tomography enhancement pattern and risk of progression[J]. J Comput Assist Tomogr, 2017, 41(3): 407-411.
[5]
Chi JL, Xu M, Zhang MR, et al. Laparoscopic versus open resection for gastric gastrointestinal stromal tumors (GISTs): A size-location-matched case-control study[J]. World J Surg, 2017, 41(9): 2345-2352.
[6]
Montemurro M, Cioffi A, Dômont J, et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)[J]. Cancer, 2018, 124(7): 1449-1454.
[7]
2013年中国胃肠道间质瘤病理诊断共识专家组. 中国胃肠道间质瘤病理诊断共识(2013年版)解读[J]. 中华病理学杂志, 2015, 44(1): 3-8.
[8]
Obata Y, Horikawa K, Takahashi T, et al. Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors[J]. Oncogene, 2017, 36(26): 3661-3672.
[9]
Giuliano K, Nagarajan N, Canner J, et al. Gastric and small intestine gastrointestinal stromal tumors: do outcomes differ?[J]. J Surg Oncol, 2017, 115(3): 351-375.
[10]
Sugita S, Hirano H, Hatanaka Y, et al. Image analysis is an excellent tool for quantifying Ki-67 to predict the prognosis of gastrointestinal stromal tumor patients[J]. Pathol Int, 2018, 68(1): 7-11.
[11]
Tan Y, Trent JC, Wilky BA, et al. Current status of immunotherapy for gastrointestinal stromal tumor[J]. Cancer Gene Ther, 2017, 24(3): 130-133.
[12]
田晓文, 梁小波, 王振华, 等. 胃肠道间质瘤术后复发危险因素及列线图的应用价值[J]. 中华消化外科杂志, 2017, 16(1): 71-76.
[13]
王峰, 宋鹏, 汪灏, 等. 284例胃间质瘤临床特征及预后分析[J/CD]. 中华普外科手术学杂志(电子版), 2017, 11(2): 123-126.
[14]
李国仁. 食管间质瘤的特征与外科治疗现状[J]. 中国肿瘤临床, 2017, 44(19): 993-999.
[15]
Huang CM, Chen QF, Lin JX, et al. Can laparoscopic surgery be applied in gastric gastrointestinal stromal tumors located in unfavorable sites?: A study based on the NCCN guidelines[J]. Medicine (Baltimore), 2017, 96(14): e6535.
[16]
Qiu HB, Zhou ZG, Feng XY, et al. Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy[J]. Medicine (Baltimore), 2018, 97(2): e9097.
[17]
Quek R, Farid M, Kanjanapan Y, et al. Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor[J]. Asia Pac J Clin Oncol, 2017, 13(3): 115-124.
[18]
王力, 高晓东, 方勇, 等. 中度复发风险胃胃肠间质瘤预后因素分析[J]. 中国实用外科杂志, 2017, 37(1): 75-78.
[19]
Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor[J]. Ann Surg Oncol, 2007, 14(7): 2018-2027.
[20]
盛友纯, 张强, 陈铭, 等. 细胞内伊马替尼浓度在胃肠道间质瘤耐药过程中的作用[J/CD]. 中华普通外科学文献(电子版), 2020, 14(2): 84-88.
[21]
杨弘鑫, 张波, 沈朝勇, 等. 伊马替尼治疗晚期及高危胃肠道间质瘤的临床疗效与安全性分析[J]. 中国普通外科杂志, 2017, 26(4): 437-442.
[1] 李钱梅, 何冠南, 赵婧, 陈曦, 唐玉英, 马丽琼, 梁蓉, 袁桃, 李明星. 早孕期低危妊娠和高危妊娠胎盘微血流成像特征及预后分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 726-732.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[8] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[9] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[10] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[11] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[12] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[13] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要